Novo Nordisk’s CEO, Lars Fruergaard Jorgensen, will step down amidst market challenges and a significant stock price drop, exceeding 50% since June 2024. Increased competition from compounded versions of Ozempic and Wegovy, along with Eli Lilly’s Zepbound gaining market share, contributed to the decision. Post navigation Why India can be a big winner of Donald Trump 2.0 era if it plays its cards right With 26 launches in 5 yrs, Hyundai to go for product blitzkrieg amidst stiff competition
